Todd A. Trapp
Net Worth
Last updated:
What is Todd A. Trapp net worth?
The estimated net worth of Mr. Todd A. Trapp is at least $10,540,769 as of 1 Nov 2022. He owns shares worth $6,068,506 as insider, has earned $1,371,093 from insider trading and has received compensation worth at least $3,101,170 in Abiomed, Inc. and Abiomed, Inc..
What is the salary of Todd A. Trapp?
Mr. Todd A. Trapp salary is $800,980 per year as Chief Financial Officer & Vice President in Abiomed, Inc.. He also receives $766,730 as Chief Financial Officer & Vice President in Abiomed, Inc..
How old is Todd A. Trapp?
Mr. Todd A. Trapp is 54 years old, born in 1971.
What stocks does Todd A. Trapp currently own?
As insider, Mr. Todd A. Trapp owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Abiomed, Inc. (ABMD) | Chief Financial Officer & Vice President | 15,927 | $381.02 | $6,068,506 |
What does Abiomed, Inc. do?
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
Todd A. Trapp insider trading
Abiomed, Inc.
Mr. Todd A. Trapp has made 7 insider trades in 2022, according to the Form 4 filled with the SEC. Most recently he sold 191 units of ABMD stock worth $72,456 on 1 Nov 2022.
The largest trade he's ever made was exercising 1,000 units of ABMD stock on 5 Jan 2022. As of 1 Nov 2022 he still owns at least 15,927 units of ABMD stock.
Abiomed key executives
Abiomed, Inc. executives and other stock owners filed with the SEC:
- Dr. David M. Weber (64) Senior Vice President & Chief Operating Officer
- Mr. Andrew J. Greenfield (52) Vice President & Chief Commercial Officer
- Mr. Marc A. Began (58) Vice President, Gen. Counsel & Sec.
- Mr. Michael R. Minogue (58) Chairman, Chief Executive Officer & Pres
- Mr. Todd A. Trapp (54) Chief Financial Officer & Vice President